All In Biotech

Drug Trial Radar · NCT01919801

Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema

Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study Evaluating the Safety & Efficacy of Icatibant as a Treatment for Angiotensin-Converting Enzyme Inhibitor (ACE-I)-Induced Angioedema in Adults

Last checked: Nov 20, 2026Latest source record: Jun 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 118 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

118

Actual

Start

Dec 2, 2013

Primary completion

Aug 22, 2015

Study completion Aug 22, 2015

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
Collaborators
PPD Development, LP
First posted
Aug 9, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted to compare the safety and efficacy of icatibant with placebo in the treatment for Angiotensin-Converting Enzyme Inhibitor (ACE-I)-Induced Angioedema in Adults.

Conditions

  • Angiotensin Converting Enzyme Inhibitor Induced Angioedema

Interventions

  • IcatibantDrug

    Single dose of 30 mg icatibant administered within 12 hours of the onset of an acute attack of ACE-I-induced angioedema

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Meeting Discharge Criteria (TMDC)Time frame: Day 0 up to Day 5
  2. Number of Participants With Treatment-emergent Adverse Events (TEAE) and Treatment-emergent Serious Adverse Events (TESAEs)Time frame: From start of study drug administration (Day 0) up to follow-up (Day 5)
  3. Number of Participants With Treatment Emergent Injection Site ReactionTime frame: Day 0 to Day 5
  4. Number of Participants With Clinically Significant Changes in Laboratory Evaluation, Vital Signs, Electrocardiogram (ECG) and Physical ExaminationTime frame: Day 0 to Day 5

Locations

55 sites in 4 countries. Site status is shown where the registry gives one.

  • University of California San Diego Medical Center

    La Jolla, California

  • University of California San Diego

    La Jolla, California

  • Washington Hospital Center

    Washington D.C., District of Columbia

  • UF Health Shands Hospital

    Gainesville, Florida

  • Orlando Health

    Orlando, Florida

  • Tampa General Hospital

    Tampa, Florida

  • Federal Health Care Center

    Chicago, Illinois

  • Cook County Hospital

    Chicago, Illinois

  • University of Kansas Cancer Center

    Kansas City, Kansas

  • Ochsner Medical Center

    New Orleans, Louisiana

  • University of Maryland School of Medicine

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Brigham and Womens Hospital

    Boston, Massachusetts

  • Baystate Medical Center

    Springfield, Massachusetts

  • Detroit Receiving Hospital and University Health Center

    Detroit, Michigan

  • Sinai Grace Hospital

    Detroit, Michigan

  • Henry Ford Health System

    Detroit, Michigan

  • William Beaumont Hospital

    Royal Oak, Michigan

  • William Beaumont Hospital

    Troy, Michigan

  • Hennepin County Medical Center

    Minneapolis, Minnesota

  • Barnes Jewish Hospital

    St Louis, Missouri

  • Washington University

    St Louis, Missouri

  • Inspira Health Network

    Vineland, New Jersey

  • University of New Mexico

    Albuquerque, New Mexico

  • Kings County Hospital Center

    Brooklyn, New York

  • SUNY Downstate Medical Center

    Brooklyn, New York

  • Weill Medical College of Cornell University

    New York, New York

  • East Carolina University

    Greenville, North Carolina

  • University of Cincinnati

    Cincinnati, Ohio

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • Ohio State University Hospital - East

    Gahanna, Ohio

  • Summit Health

    Chambersburg, Pennsylvania

  • Hahnemann University Hospital

    Philadelphia, Pennsylvania

  • Temple University Hospital

    Philadelphia, Pennsylvania

  • Albert Einstein Medical Center

    Philadelphia, Pennsylvania

  • Allegheny General Hospital

    Pittsburgh, Pennsylvania

  • Rhode Island Hospital

    Providence, Rhode Island

  • University of South Carolina School of Medicine

    Columbia, South Carolina

  • Baylor University Medical Center

    Dallas, Texas

  • John Peter Smith Hospital

    Fort Worth, Texas

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.